	US 12,275,778 B2
	Anti-troponin T antibodies
Frank Kroner, Geretsried-Gelting (DE); Michael Schraeml, Penzberg (DE); and Sarah Liedke, Penzberg (DE)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Sep. 9, 2020, as Appl. No. 17/015,662.
Application 17/015,662 is a continuation of application No. PCT/EP2019/056069, filed on Mar. 12, 2019.
Claims priority of application No. 18161697 (EP), filed on Mar. 14, 2018.
Prior Publication US 2021/0009668 A1, Jan. 14, 2021
Int. Cl. C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/18 (2013.01) [G01N 33/6887 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/4712 (2013.01); G01N 2800/325 (2013.01)]

10 Claims

1. An antibody that specifically binds to human cardiac troponin T (SEQ ID NO:1) being characterized in that the CDRs comprise in the light chain variable domain a CDR1 comprising the amino acid sequence of SEQ ID NO:2, a CDR2 comprising the amino acid sequence of SEQ ID NO:3, and a CDR3 comprising the amino acid sequence of SEQ ID NO:4, and in the heavy chain variable domain one of the following:

(i) a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12,

(ii) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11,

(iii) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 13,

(iv) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 13,

(v) a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10,

(vi) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11,

(vii) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12,

(viii) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10,

(ix) a CDR1 comprising the amino acid sequence of SEQ ID NO:7, a CDR2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or

(x) a CDR1 comprising the amino acid sequence of SEQ ID NO:5, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12.